Insulet (US:PODD) ZACKSยท2025-05-05 14:22Core Viewpoint - Wall Street analysts expect Insulet (PODD) to report quarterly earnings of $0.81 per share, reflecting an 11% year-over-year increase, with revenues projected at $541.33 million, a 22.6% increase compared to the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised down by 1.1% in the past 30 days, indicating a reassessment by covering analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Revenue Projections - Analysts estimate 'Revenue- Total Omnipod' at $534.28 million, representing a 23.4% increase year-over-year [5]. - 'Revenue- Drug Delivery' is expected to reach $7.37 million, indicating a decline of 15.3% year-over-year [5]. - 'Revenue- International Omnipod' is projected at $144.78 million, reflecting a 25.6% increase year-over-year [5]. - 'Revenue- U.S. Omnipod' is estimated at $389.50 million, showing a 22.6% increase from the prior-year quarter [6]. Stock Performance - Over the past month, Insulet shares have returned +4.8%, outperforming the Zacks S&P 500 composite's +0.4% change [6]. - Currently, Insulet carries a Zacks Rank 4 (Sell), suggesting potential underperformance in the near future [6].